Abstract
effectiveness of LY293111 in vivo with dynamic monitoring of tumor progression. The welldifferentiated human pancreatic cancer cell line $2-0 I3, with stable expression of enhanced green fluorescent protein was used. Cells (Sx105) in 10 i~l MEM were injected into the duodenal lobe of the pancreas of athymic mice. The surgical procedure and weekly examinations were monitored using a stereo fluorescence microscope combined with an imaging system. Image quality was improved by a reversible skin-flap. We compared 4 groups with 8 mice/group: control (no treatment); LY293111; gemcitabine; LY293111 + gemcitabine. kY293111 was administered daily p.o. and gemcitabina injected 4 times i.p. Animals were euthanized 4 weeks after surgery. A staging system was developed to evaluate the tumor progression according to the TNM-classification. All 32 animals injected with $2-013 cells developed pancreatic cancer. Within 4 weeks, the control animals developed end-stage disease with invasive cancer obstructing the duodenum and bile duct, liver, lung and lymph node metastases, peritoneal carcinomatosis with malignant ascites and cachex~a. All treatment groups showed sigmficant inhibition of tumor growth and metastases. The combined treatment group with gemcitabine & LY293111 showed the greatest tumor suppression according to the scoring system, tumor weight and area. This cancer model allows sensitive detection of tumor growth, metastases and angiogenesis over time, mimics the clinical signs of pancreatic cancer in humans and has proven to be valuable for studying in vivo tumor behaviour and response to therapeutic agents. LY293111, especially in combination with gemcitahine, markedly inhibited cancer growth and prevented liver metastases. In conclusion, LY293111 is a new and promising therapeutic agent for adjuvant as well as palliative therapy of pancreatic adenocarcinoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
